Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sandrine Zweifel

Showing results (81-90 of 85) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 85 results.
Ophthalmology and Therapy|February 3, 2026
One-Year Real-World Outcomes of Aflibercept 8 mg in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network ReportGabriela Grimaldi, Nicolò Bartolomeo, Justus G Garweg, et al.
Ophthalmology and Therapy|February 28, 2026
Correction: One-Year Outcomes of Faricimab in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network ReportAnne Tillmann, Richard Stillenmunkes, Justus G Garweg, et al.
Ophthalmology and Therapy|March 4, 2026
One-Year Real-World Outcomes of Switching to Aflibercept 8 mg in Eyes with Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network ReportAlice M Kitay, Anne Tillmann, Isabel Pfister, et al.
Ophthalmology. Retina|March 26, 2025
One-Year Outcomes after Switching to Faricimab in Eyes with Pretreated Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network ReportGabriela Grimaldi, Aude Ambresin, Isabel B Pfister, et al.
Journal of Biophotonics|October 5, 2023
Human selection bias drives the linear nature of the more ground truth effect in explainable deep learning optical coherence tomography image segmentationPeter M Maloca, Maximilian Pfau, Lucas Janeschitz-Kriegl, et al.
Pageof 9

Showing results (81-90 of 85) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 85 results.
Ophthalmology and Therapy|February 3, 2026
One-Year Real-World Outcomes of Aflibercept 8 mg in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network ReportGabriela Grimaldi, Nicolò Bartolomeo, Justus G Garweg, et al.
Ophthalmology and Therapy|February 28, 2026
Correction: One-Year Outcomes of Faricimab in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network ReportAnne Tillmann, Richard Stillenmunkes, Justus G Garweg, et al.
Ophthalmology and Therapy|March 4, 2026
One-Year Real-World Outcomes of Switching to Aflibercept 8 mg in Eyes with Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network ReportAlice M Kitay, Anne Tillmann, Isabel Pfister, et al.
Ophthalmology. Retina|March 26, 2025
One-Year Outcomes after Switching to Faricimab in Eyes with Pretreated Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network ReportGabriela Grimaldi, Aude Ambresin, Isabel B Pfister, et al.
Journal of Biophotonics|October 5, 2023
Human selection bias drives the linear nature of the more ground truth effect in explainable deep learning optical coherence tomography image segmentationPeter M Maloca, Maximilian Pfau, Lucas Janeschitz-Kriegl, et al.
Pageof 9